Table 1.
Japanese studies investigating risk of HCC among noncirrhotic HCV patients following IFN therapy and SVR.
| Study | Date | Study type | Number of patients with SVR | Mean follow-up prior to and after SVR, months | Number of patients with SVR who developed HCC (%) | Number of patients developing HCC by stage of fibrosis (%) | Annual incidence rate for sustained responders (by stage when available) | Mean number of months from SVR to HCC diagnosis |
|---|---|---|---|---|---|---|---|---|
| Enokimura, et al (3)2003 | 2003 | Prospective | 142 | --- | 6 (4.2) | --- | 0.61% | 59.2 |
| Iwasaki, et al (4) | 2004 | Prospective | 792 | 62 | 23 (2.9) | F1: 4 (17.4) F2: 4 (17.4) F3: 12 (52.2) F4: 3 (13.0) |
F0–2: 0.2% F3–4: 2.9% |
--- |
| Okanoue, et al (5) | 1999 | Prospective | 316 | 40–46 | 3 (0.9) | F3: 3 (100.0) | F1: 0% F2: 0% F3: 1.2% F4: 0% |
32.4 |
| Shindo, et al (6) | 2001 | Prospective | 67 | ≥96 | 2 (3.0) | --- | 0.37% | 47 |
| Takimoto, et al (7) | 2002 | Retrospective | 201 | 81.6 | --- | --- | 0.29% | --- |
| Tanaka, et al (8) | 2000 | Prospective | 175 | 59.6 | 3 (1.7) | --- | 0.35% | --- |
| Yoshida, et al (9) | 1999 | Prospective | 789 | 51.6 | 10 (1.3) | F0/1: 1 (10.0) F2: 1 (10.0) F3: 7 (70.0) F4: 1 (10.0) |
F0/1: 0.11% F2: 0.10% F3: 1.29% F4: 0.49% |
--- |
| Total | --- | --- | 2,482 | --- | 47 (1.9) | F0/1: 5 (13.9) F2: 5 (13.9) F3: 22 (61.1) F0–F3: 32 (88.9) F4: 4 (11.1) |
--- | --- |